Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study

Background KCNJ11 mutations cause permanent neonatal diabetes through pancreatic ATP-sensitive potassium channel activation. 90% of patients successfully transfer from insulin to oral sulfonylureas with excellent initial glycaemic control; however, whether this control is maintained in the long term is unclear. Sulfonylurea failure is seen in about 44% of people with type 2 diabetes after 5 years of treatment. Therefore, we did a 10-year multicentre follow-up study of a large international cohort of patients with KCNJ11 permanent neonatal diabetes to address the key questions relating to long-term efficacy and safety of sulfonylureas in these patients. Methods In this multicentre, international cohort study, all patients diagnosed with KCNJ11 permanent neonatal diabetes at five laboratories in Exeter (UK), Rome (Italy), Bergen (Norway), Paris (France), and Krakow (Poland), who transferred from insulin to oral sulfonylureas before Nov 30, 2006, were eligible for inclusion. Clinicians collected clinical characteristics and annual data relating to glycaemic control, sulfonylurea dose, severe hypoglycaemia, side-effects, diabetes complications, and growth. The main outcomes of interest were sulfonylurea failure, defined as permanent reintroduction of daily insulin, and metabolic control, specifically HbA(1c) and sulfonylurea dose. Neurological features associated with KCNJ11 permanent neonatal diabetes were also assessed. Findings 90 patients were identified as being eligible for inclusion and 81 were enrolled in the study and provided long-term (>5.5 years cut-off) outcome data. Median follow-up duration for the whole cohort was 10.2 years (IQR 9.3-10.8). At most recent follow-up (between Dec 1, 2012, and Oct 4, 2016), 75 (93%) of 81 participants remained on sulfonylurea therapy alone. Excellent glycaemic control was maintained for patients for whom we had paired data on HbA(1c) and sulfonylurea at all time points (ie, pre-transfer [for HbA(1c)], year 1, and most recent followup; n=64)-median HbA(1c) was 8.1% (IQR 7.2-9.2; 65.0 mmol/mol [55.2-77.1]) before transfer to sulfonylureas, 5.9% (5.4-6.5; 41.0 mmol/mol [35.5-47.5]; p<0.0001 vs pre-transfer) at 1 year, and 6.4% (5.9-7.3; 46.4 mmol/mol [41.0-56.3]; p<0.0001 vs year 1) at most recent follow-up (median 10.3 years [IQR 9.2-10.9]). In the same patients, median sulfonylurea dose at 1 year was 0.30 mg/kg per day (0.14-0.53) and at most recent follow-up visit was 0.23 mg/kg per day (0.12-0.41; p=0.03). No reports of severe hypoglycaemia were recorded in 809 patient-years of follow-up for the whole cohort (n=81). 11 (14%) patients reported mild, transient side-effects, but did not need to stop sulfonylurea therapy. Seven (9%) patients had microvascular complications; these patients had been taking insulin longer than those without complications (median age at transfer to sulfonylureas 20.5 years [IQR 10.5-24.0] vs 4.1 years [1.3-10.2]; p=0.0005). Initial improvement was noted following transfer to sulfonylureas in 18 (47%) of 38 patients with CNS features. After long-term therapy with sulfonylureas, CNS features were seen in 52 (64%) of 81 patients. Interpretation High-dose sulfonylurea therapy is an appropriate treatment for patients with KCNJ11 permanent neonatal diabetes from diagnosis. This therapy is safe and highly effective, maintaining excellent glycaemic control for at least 10 years. Copyright (C) 2018 The Author(s). This is an Open Access article under the CC BY 4.0 license.